GeneDx sold off on quarter-over-quarter pricing concerns even though it makes plenty of money, has ridiculous upside optionality and a solid chance of executing on it in the medium term. x.com  x.com 

Biodesix's technology could become strategically important to multiple acquirers as more multicancer screening finds lung nodules needing risk stratification. Its shares trade at 2.63x gross profit, and growth should reach 23-24% when it reports on November 5. Chief Scientific Officer Gary Pestano's November 11 MRD talk is another point to watch. Permanent capital loss remains possible. x.com 

GeneDx is still worth a lot more and is the first position in an AI and biotech thematic basket. It came up in a screen with recent insider buying and appears fairly anti-correlated with the AI trade. x.com 

NeoGenomics is firing on all cylinders at new all-time highs after a power gap on its recent earnings, in the strong genetic-testing corner of medical devices. It carries a rare A+ accumulation grade and a 97 relative-strength rating, and surfaced on a 'Power PEG' screen. x.com 

Personalis is following Natera's playbook, moving its revenue inflection from theoretical to measurable. In 2026 it is deliberately buying share over margin, guiding 43K-45K clinical tests but only $10-11M of clinical revenue. Four Medicare coverages across breast cancer, lung cancer and immunotherapy monitoring each open multiyear surveillance. If conversion tracks Natera, revenue could reach $175-220M in 2027 and $320-400M in 2028. Tempus agreed to acquire it at $16.25 per share. x.com 

Caris Life Sciences reads the full exome while Tempus AI reads 648 genes, a difference that should show the value of proprietary data. x.com 

Bio-diagnostics offers the best value in the market, trading at lower price-to-sales multiples than software with low correlation to the AI trade. Its data-services businesses should become increasingly important because of AI. Tempus is the key name to understand, with smaller players including Exagen, Quanterix and GeneDx in the theme, and Caris Life Sciences just posted great results. x.com  x.com 

BillionToOne is taking share in both prenatal testing and oncology thanks to patented technology that makes its tests more sensitive and specific. It is the only diagnostic peer that is GAAP profitable, and it may be best positioned to offer a genuinely useful early cancer detection test, adding optionality. On revenue it looks pricier, but its real comparables, Natera and Guardant Health, are about 50% more expensive while growing more slowly and earning less. x.com  x.com 

Tempus AI has a data moat no one has replicated: a multimodal, patient-linked genomic, clinical and imaging dataset at scale. It holds over 8 million imaging files, 1.5 million matched clinical and molecular profiles and 4.5 million sequencing samples, which drug companies leaning on AI increasingly need. It is expanding from oncology into cardiology, neuropsychiatry and radiology. Revenue grows 25% and gross margin rose from 32% in 2021 to 64%, though last quarter's profit was a one-time item. … Show more

Tempus AI is becoming a bigger health-tech player as pharma deals add a new services revenue stream beyond selling tests. BTIG's Mark Massaro raised his target to $80 from $70 with a Buy rating, mainly because Tempus will be the sequencing provider for Moderna and Merck's cancer vaccine program. The Personalis deal and MRD momentum add to a strengthening long-term AI and precision-oncology story, despite near-term volatility. x.com